DNER and diffuse large B-cell lymphoma: Burkitt’s lymphoma (BL) cell lines DG-75 and RAJI and diffuse large B-cell lymphoma (DLBCL) cell lines SU-DHL-4 and U-2946 were exposed to dose ranges of isoform-specific bivalent BET inhibitor AZD5153 (AZD) or pan-BET inhibitor I-BET 151 (I-BET) (0.001–10 μM) for 24 h, 48 h and 72 h (Figure 1).